ARROWHEAD PHARMACEUTICALS, INC.
Price data unavailable
Track ARWR in your trading journalAbout ARROWHEAD PHARMACEUTICALS, INC.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is a publicly listed company on US equity markets.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
The company reports trailing twelve-month revenue of $11.26M and net loss of $132.73M.
Key metrics include a return on equity of -21.6%.
Use FINOTAUR to track ARWR's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $11.26M |
| Net Income (TTM) | $-132.73M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -21.62% |
| Debt-to-Equity | — |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Apr 30
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight
- GlobeNewswire Inc.·Apr 29
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
- Benzinga·Feb 13
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
Want real-time analysis on ARWR?
Track it free in your trading journal. Log trades, tag setups, and review your edge.